Category - Developments

Developments

Imagin Medical i/Blue imaging system on schedule for design verification

Imagin Medical (CSE:IME; OTCQB:IMEXF) is making progress towards design verification of its i/Blue Imaging System functional product. The company has purchased and received components from established suppliers to meet...

November 12, 2019

Developments

Cellular Biomedicine receives going private proposal

The board of Cellular Biomedicine Group (NASDAQ:CBMG) received a preliminary non-binding proposal from a consortium led by Tony Liu, CEO of Cellular, to acquire all the shares outstanding at a price of $19.50 each in a...

November 11, 2019

Developments

Liminal BioSciences presents new preclinical data at ASN Kidney Week

Liminal BioSciences (TSX:LMNL; OTCQX:PFSCF) and its collaborators presented new preclinical findings on a novel therapeutic approach to the treatment of inflammatory and fibrosis-related kidney diseases at the American...

November 11, 2019

Developments

Study finds therapeutic role for cannabis in PTSD depression

A new study in the peer-reviewed Journal of Psychopharmacology suggests that cannabis has an uplifting effect on people with post traumatic stress disorder (PTSD) and may a therapeutic role in addressing the condition...

November 8, 2019

Developments

Hepion to present on CRV431’s anti-fibrotic activity at the Liver Meeting 2019

Hepion Pharmaceuticals’ (NASDAQ:HEPA) CSO, Dr. Daren Ure, will present preclinical data on CRV431 at The Liver Meeting 2019. Dr. Ure’s presentation will address CRV431’s ability to decrease liver fibrosis in a carbon...

November 7, 2019

Developments

Opsens in first clinical use of OptoWire III after Health Canada approval

Opsens (TSX:OPS; OTCQX:OPSSF) announced the world’s first clinical use of its OptoWire III at the Quebec Heart and Lung Institute, following Health Canada’s recent approval of the device. OptoWire III is a...

November 7, 2019

Developments

Hepion CRV431 reduces fibrosis in new model of NASH

Hepion Pharmaceuticals (NASDAQ:HEPA) reported preclinical findings where CRV431, a novel cyclophilin inhibitor, significantly decreased the extent of liver fibrosis in a Western diet (WD) animal model of NASH. The WD...

November 7, 2019

Developments

BDC spinout, Amplitude Ventures, launches $200-million life sciences venture fund

Amplitude Ventures of Montreal has launched a $200-million venture fund, closing more than 50% of its target. Amplitude is a spinout of the Business Development Bank of Canada, which is a cornerstone investor in...

November 7, 2019

Developments

Inovio Pharma reports positive interim data from Phase 2 glioblastoma trial

Inovio Pharmaceuticals (NASDAQ:INO) reported positive interim results from its Phase 2 study of INO-5401 for the treatment of newly-diagnosed glioblastoma multiforme (GBM), the most common and aggressive type of brain...

November 5, 2019

Developments

Notch Therapeutics to commercialize industrial-scale T cell therapies

Upstart Notch Therapeutics plans to commercialize industrial-scale allogeneic gene-edited T cell therapies to deliver cost-effective treatments to patients with cancer or immune deficiencies. Incubated at Toronto’s...

November 5, 2019

Category - Developments

Imagin Medical i/Blue imaging system on schedule for design verification

Cellular Biomedicine receives going private proposal

Liminal BioSciences presents new preclinical data at ASN Kidney Week

Study finds therapeutic role for cannabis in PTSD depression

Hepion to present on CRV431’s anti-fibrotic activity at the Liver Meeting 2019

Opsens in first clinical use of OptoWire III after Health Canada approval

Hepion CRV431 reduces fibrosis in new model of NASH

BDC spinout, Amplitude Ventures, launches $200-million life sciences venture fund

Inovio Pharma reports positive interim data from Phase 2 glioblastoma trial

Notch Therapeutics to commercialize industrial-scale T cell therapies

General

More